Abstract: A system for validating a hologram on a document is provided. The system includes a camera for taking plurality of images of the hologram, a memory for storing the plurality of images, a display for displaying at least one of the images and for instructing a user to rotate the document such that at least two of the images are taken from different hologram viewing angles, and a processor for analysing the characteristics of the hologram in each of the plurality of images and for determining whether any of the characteristics match a predetermined characteristic set for a predetermined hologram type.

Abstract: A system and method for detecting a heart rate of a user using a portable electronic device is provided. The system includes a first camera mounted to the portable electronic device for taking a series of photographs of the user, a memory for storing the series of photographs including the RGB tone colour details of each pixel for each photograph, and a processor for removing the red and blue tones from each image and for measuring the variation in green tone between each image thereby detecting the heart rate of the user.

Abstract: A system for validating a hologram on a document is provided. The system includes a camera for taking plurality of images of the hologram, a memory for storing the plurality of images, a display for displaying at least one of the images and for instructing a user to rotate the document such that at least two of the images are taken from different hologram viewing angles, and a processor for analysing the characteristics of the hologram in each of the plurality of images and for determining whether any of the characteristics match a predetermined characteristic set for a predetermined hologram type.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Psendomonas spp., Yersinia spp., en tero pathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Psendomonas spp., Yersinia spp., en tero pathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Pseudomonas spp., Yersinia spp., enteropathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.

Abstract: Organic compounds showing the ability to inhibit bacterial omptin proteases, specifically Yersinia pestis plasminogen activator (Pla) are disclosed. The disclosed Y. pestis plasminogen activator inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by Y. pestis.